化療引起的貧血市場 - 全球產業規模、佔有率、趨勢、機會和預測，按疾病類型、治療類型、藥物類型、最終用戶、地區和競爭細分，2020-2030 年預測

2024 年全球化療引起的貧血 (CIA) 市場價值為 28.6 億美元，預計到 2030 年將達到 43.1 億美元，預測期內的年複合成長率(CAGR) 為 7.02%。化療引起的貧血市場已成為腫瘤學領域的重點，化療是癌症患者的主要治療方法。隨著化療的應用不斷增加，化療引起的貧血的盛行率也隨之增加。這種疾病不僅影響癌症患者的生活品質，也為製藥公司和醫療保健提供者帶來了巨大的商機。

化療引起的貧血是化療的常見副作用，是由於化療藥物損害骨髓產生紅血球的能力，從而降低血液中的血紅蛋白水平而發生的。這種情況會導致疲勞、虛弱、呼吸急促以及對進一步癌症治療的耐受性降低等症狀。因此，CIA 的管理已成為癌症治療的關鍵方面，從而導致對有效治療的需求增加。

CIA 影響著廣泛的癌症患者，美國癌症協會報告稱，30-90% 接受化療的癌症患者會出現不同程度的貧血。 CIA 的治療方法包括紅血球生成促效劑 (ESA)、鐵補充劑、輸血和新興療法。 ESA，包括促紅血球生成素促效劑和達貝泊汀α，一直被廣泛用於治療這種疾病，但安全問題和監管變化影響了它們的使用。 CIA 市場的關鍵參與者包括安進、強生和羅氏等大型製藥公司，這些公司正在開發和行銷針對這種疾病的治療方法。

CIA 市場充滿活力，既充滿挑戰也充滿機會。監管問題和報銷問題構成了重大障礙，但持續的研究、以患者為中心的護理、行業合作和市場擴張帶來了光明的未來。隨著醫療保健產業繼續優先考慮癌症患者的健康，CIA 管理的進步對於改善化療患者的生活品質至關重要。製藥公司和醫療保健提供者必須保持敏捷和創新，以滿足不斷成長的患者群體的需求。

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第 5 章：全球化療引起的貧血市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依疾病類型（輕度貧血、中度貧血、重度貧血）
  • 依治療類型（紅血球輸注、紅血球生成促效劑 (ESA)、鐵補充劑）
  • 依藥物類型（Epogen 注射、Procrit 注射、Androxy 口服液、Aranesp 注射、Epoetin Alfa 注射、其他）
  • 按最終使用者（醫院和診所、門診護理中心、其他）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第 6 章：北美化療引起的貧血市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 加拿大
  • 墨西哥

第 7 章：歐洲化療引起的貧血市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 英國
  • 義大利
  • 法國
  • 西班牙

第 8 章：亞太地區化療引起的貧血市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 印度
  • 日本
  • 韓國
  • 澳洲

第 9 章：南美洲化療引起的貧血市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲化療引起的貧血市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 合併與收購（如有）
• 產品發布（如果有）
• 最新動態

第 13 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 14 章：競爭格局

• Dr. Reddy's Laboratories Ltd.
• Pfizer Inc.
• Panacea Biotec Limited
• SBI Pharmaceuticals Co., Ltd
• Sumitomo Dainippon Pharma Co., Ltd.
• PharmaEssentia Corp.
• PhytoHealth Corp
• UBI Pharma Inc.
• Amgen Inc.
• Astellas Pharma Inc.

第 15 章：策略建議

第16章 關於出版商,免責事項

The Global Chemotherapy-Induced Anemia (CIA) Market was valued at USD 2.86 billion in 2024 and is projected to reach USD 4.31 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.02% during the forecast period. The market for chemotherapy-induced anemia has become a significant focus within the oncology sector, with chemotherapy being a primary treatment for cancer patients. As chemotherapy use continues to rise, the prevalence of chemotherapy-induced anemia has concurrently increased. This condition not only impacts cancer patients' quality of life but also presents substantial business opportunities for pharmaceutical companies and healthcare providers.

Chemotherapy-induced anemia is a common side effect of chemotherapy, occurring when chemotherapy drugs impair the bone marrow's ability to produce red blood cells, thereby reducing hemoglobin levels in the blood. This condition can result in symptoms such as fatigue, weakness, shortness of breath, and a reduced tolerance for further cancer treatments. As a result, the management of CIA has become a key aspect of cancer care, leading to increased demand for effective treatments.

CIA affects a wide range of cancer patients, with the American Cancer Society reporting that 30-90% of cancer patients undergoing chemotherapy experience varying degrees of anemia. Treatments for CIA include erythropoiesis-stimulating agents (ESAs), iron supplements, blood transfusions, and emerging therapies. ESAs, including erythropoietin-stimulating agents and darbepoetin alfa, have been commonly used to manage the condition, although safety concerns and regulatory changes have impacted their usage. Key players in the CIA market include major pharmaceutical companies such as Amgen, Johnson & Johnson, and Roche, which are developing and marketing treatments for this condition.

The CIA market is dynamic, presenting both challenges and opportunities. Regulatory concerns and reimbursement issues pose significant hurdles, but ongoing research, patient-centered care, industry collaboration, and market expansion offer a promising future. As the healthcare industry continues to prioritize cancer patient well-being, advancements in CIA management will be crucial to improving the quality of life for those undergoing chemotherapy. Pharmaceutical companies and healthcare providers must remain agile and innovative to meet the needs of this growing patient population.

Key Market Drivers

Increasing Incidence of Cancer: The global incidence of cancer is a significant driver of the chemotherapy-induced anemia market. As cancer cases continue to rise, so does the demand for effective treatments, including chemotherapy. Despite its effectiveness, chemotherapy is associated with side effects such as CIA, which is gaining increased attention. The rising cancer incidence is prompting research, innovation, and the development of therapies to manage this condition.

According to the World Cancer Research Fund, there were 19,976,499 cancer cases worldwide in 2022, including non-melanoma skin cancer. Excluding non-melanoma skin cancer, the number of cases was 18,741,966, with nearly equal distribution between men (9,566,825 cases) and women (9,175,141 cases).

Key Market Challenges

Regulatory Barriers: Regulatory hurdles pose significant challenges for companies in the CIA market. Navigating the complex regulatory environment requires substantial resources and time. Regulatory agencies, including the FDA and EMA, require extensive preclinical and clinical data to evaluate the safety and efficacy of new therapies. This process is often lengthy and costly, delaying time to market and increasing financial strain for companies. Regulatory requirements also vary across regions, further complicating international market expansion. Smaller firms, in particular, face challenges competing with larger, more established companies with greater resources and experience in managing regulatory processes.

Key Market Trends

Rising Awareness and Early Diagnosis of Chemotherapy-Induced Anemia: Increasing awareness and early diagnosis of CIA is a major driver of the global market. As cancer incidence grows and treatment regimens become more complex, there is greater recognition of the impact of chemotherapy-induced anemia on patients' quality of life. Previously underdiagnosed or underappreciated, CIA is now receiving more attention from healthcare professionals, leading to an increased demand for treatment options.

Key Market Players

• Dr. Reddy's Laboratories Ltd.
• Pfizer Inc.
• Panacea Biotec Limited
• SBI Pharmaceuticals Co., Ltd.
• Sumitomo Dainippon Pharma Co., Ltd.
• PharmaEssentia Corp.
• PhytoHealth Corp
• UBI Pharma Inc.
• Amgen Inc.
• Astellas Pharma Inc.

Report Scope

This report segments the Global Chemotherapy-Induced Anemia Market as follows:

By Disease Type:

• Mild Anemia
• Moderate Anemia
• Severe Anemia

By Treatment Type:

• RBC Transfusions
• Erythropoiesis-Stimulating Agents (ESAs)
• Iron Supplementation

By Drug Type:

• Epogen Injection
• Procrit Injection
• Androxy Oral
• Aranesp Injection
• Epoetin Alfa Injection
• Others

By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

By Region:

• North America: United States, Canada, Mexico
• Europe: France, United Kingdom, Italy, Germany, Spain
• Asia-Pacific: China, India, Japan, Australia, South Korea
• South America: Brazil, Argentina, Colombia
• Middle East & Africa: South Africa, Saudi Arabia, UAE

Competitive Landscape

This section provides a detailed analysis of the major companies operating in the Chemotherapy-Induced Anemia Market.

Available Customizations

The Global Chemotherapy-Induced Anemia market report offers the following customizations tailored to the needs of specific companies:

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Chemotherapy-Induced Anemia Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Type (Mild Anemia, Moderate Anemia, Severe Anemia)
  • 5.2.2. By Treatment Type (RBC Transfusions, Erythropoiesis-stimulating agents (ESAs), Iron Supplementation)
  • 5.2.3. By Drug Type (Epogen Injection, Procrit Injection, Androxy Oral, Aranesp injection, Epoetin Alfa Injection, Others)
  • 5.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Chemotherapy-Induced Anemia Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type
  • 6.2.2. By Treatment Type
  • 6.2.3. By Drug Type
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Chemotherapy-Induced Anemia Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Type
      • 6.3.1.2.2. By Treatment Type
      • 6.3.1.2.3. By Drug Type
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Chemotherapy-Induced Anemia Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Type
      • 6.3.2.2.2. By Treatment Type
      • 6.3.2.2.3. By Drug Type
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Chemotherapy-Induced Anemia Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Type
      • 6.3.3.2.2. By Treatment Type
      • 6.3.3.2.3. By Drug Type
      • 6.3.3.2.4. By End User

7. Europe Chemotherapy-Induced Anemia Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Treatment Type
  • 7.2.3. By Drug Type
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Chemotherapy-Induced Anemia Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Treatment Type
      • 7.3.1.2.3. By Drug Type
      • 7.3.1.2.4. By End User
  • 7.3.2. United Kingdom Chemotherapy-Induced Anemia Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Treatment Type
      • 7.3.2.2.3. By Drug Type
      • 7.3.2.2.4. By End User
  • 7.3.3. Italy Chemotherapy-Induced Anemia Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Treatment Type
      • 7.3.3.2.3. By Drug Type
      • 7.3.3.2.4. By End User
  • 7.3.4. France Chemotherapy-Induced Anemia Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease Type
      • 7.3.4.2.2. By Treatment Type
      • 7.3.4.2.3. By Drug Type
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Chemotherapy-Induced Anemia Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease Type
      • 7.3.5.2.2. By Treatment Type
      • 7.3.5.2.3. By Drug Type
      • 7.3.5.2.4. By End User

8. Asia-Pacific Chemotherapy-Induced Anemia Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Treatment Type
  • 8.2.3. By Drug Type
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Chemotherapy-Induced Anemia Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Treatment Type
      • 8.3.1.2.3. By Drug Type
      • 8.3.1.2.4. By End User
  • 8.3.2. India Chemotherapy-Induced Anemia Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Treatment Type
      • 8.3.2.2.3. By Drug Type
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Chemotherapy-Induced Anemia Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Treatment Type
      • 8.3.3.2.3. By Drug Type
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Chemotherapy-Induced Anemia Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease Type
      • 8.3.4.2.2. By Treatment Type
      • 8.3.4.2.3. By Drug Type
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Chemotherapy-Induced Anemia Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease Type
      • 8.3.5.2.2. By Treatment Type
      • 8.3.5.2.3. By Drug Type
      • 8.3.5.2.4. By End User

9. South America Chemotherapy-Induced Anemia Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Treatment Type
  • 9.2.3. By Drug Type
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Chemotherapy-Induced Anemia Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Treatment Type
      • 9.3.1.2.3. By Drug Type
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Chemotherapy-Induced Anemia Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Treatment Type
      • 9.3.2.2.3. By Drug Type
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Chemotherapy-Induced Anemia Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Treatment Type
      • 9.3.3.2.3. By Drug Type
      • 9.3.3.2.4. By End User

10. Middle East and Africa Chemotherapy-Induced Anemia Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease Type
  • 10.2.2. By Treatment Type
  • 10.2.3. By Drug Type
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Chemotherapy-Induced Anemia Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease Type
      • 10.3.1.2.2. By Treatment Type
      • 10.3.1.2.3. By Drug Type
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Chemotherapy-Induced Anemia Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease Type
      • 10.3.2.2.2. By Treatment Type
      • 10.3.2.2.3. By Drug Type
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Chemotherapy-Induced Anemia Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease Type
      • 10.3.3.2.2. By Treatment Type
      • 10.3.3.2.3. By Drug Type
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Dr. Reddy's Laboratories Ltd.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Pfizer Inc.
• 14.3. Panacea Biotec Limited
• 14.4. SBI Pharmaceuticals Co., Ltd
• 14.5. Sumitomo Dainippon Pharma Co., Ltd.
• 14.6. PharmaEssentia Corp.
• 14.7. PhytoHealth Corp
• 14.8. UBI Pharma Inc.
• 14.9. Amgen Inc.
• 14.10. Astellas Pharma Inc.

15. Strategic Recommendations

16. About Us & Disclaimer